Review
Cardiac & Cardiovascular Systems
Flavio D'Ascenzi, Caterina Fiorentini, Francesca Anselmi, Sergio Mondillo
Summary: Athletes' hearts undergo remodeling due to exercise, but this can sometimes be mistaken for pathological hypertrophy seen in cardiac disorders like hypertension. Differentiating between athlete's heart and hypertensive heart disease can be challenging due to similar changes in left ventricular mass and wall thickness caused by training.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY
(2021)
Article
Cardiac & Cardiovascular Systems
Ping Guan, Jun Gu, Zhi-ping Song, Chang-qian Wang, Wei Hu, Jun-feng Zhang
Summary: This study found that a quarter of patients with hypertensive left ventricular hypertrophy and HFpEF progress to systolic dysfunction during a 5-year follow-up, with poor clinical outcomes. Beta-blocker therapy may play a protective role in preserving LVEF, and the transition of LV geometry is uncommon.
Article
Cell Biology
Shan Tu, Zhi-Jie Shen, Xiao-Yan Wang, Li-Xiong Zeng, Zhi-Hui Zhang
Summary: The study found that renal sympathetic denervation effectively reduced hyperlipidity-induced cardiac hypertrophy in beagle dogs by lowering blood pressure levels, reducing left ventricular mass and fibrosis, and improving left ventricular function. The mechanisms may involve decreased levels of norepinephrine and angiotensin II in the circulation and myocardial tissues, leading to delayed occurrence of left ventricular remodeling.
MEDIATORS OF INFLAMMATION
(2021)
Article
Cardiac & Cardiovascular Systems
Thu-Thao Le, Vanessa Lim, Rositaa Ibrahim, Muh-Tyng Teo, Jennifer Bryant, Briana Ang, Boyang Su, Tar-Choon Aw, Chi-Hang Lee, Jeroen Bax, Stuart Cook, Calvin W. L. Chin
Summary: The newly derived remodelling index (RI) provides prognostic value in risk stratification of hypertensive left ventricular hypertrophy (LVH), with patients with low RI showing a significantly higher risk of adverse events compared to those with normal RI. Concentric and eccentric LVH are associated with similar adverse prognosis, indicating the potential clinical implications of the RI in predicting cardiovascular events in hypertensive patients with LVH.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR IMAGING
(2021)
Article
Cardiac & Cardiovascular Systems
Alessandro Giollo, Giovanni Cioffi, Federica Ognibeni, Riccardo Bixio, Angelo Fassio, Giovanni Adami, Giovanni Orsolini, Andrea Dalbeni, Luca Idolazzi, Davide Gatti, Maurizio Rossini, Ombretta Viapiana
Summary: Among stable rheumatoid arthritis (RA) patients, women have the highest predisposition for left ventricular hypertrophy (LVH), with significant increase in LV mass observed only in women.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2021)
Article
Biochemistry & Molecular Biology
Yuta Okamura, Ryo Niijima, Satoshi Kameshima, Tomoko Kodama, Kosuke Otani, Muneyoshi Okada, Hideyuki Yamawaki
Summary: Hypertension is a major risk factor for cardiovascular diseases, caused by various abnormalities including blood vessel contractibility. This study investigated the effects of human omentin-1 on hypertensive complications in aged SHR. It was found that omentin-1 tended to improve left ventricular and renal failure in SHR, indicating its potential therapeutic role in hypertensive complications.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Plant Sciences
Nurmila Sari, Yasufumi Katanasaka, Yuga Sugiyama, Yoichi Sunagawa, Yusuke Miyazaki, Masafumi Funamoto, Satoshi Shimizu, Kana Shimizu, Akira Murakami, Kiyoshi Mori, Hiromichi Wada, Koji Hasegawa, Tatsuya Morimoto
Summary: The study demonstrates that Zerumbone can inhibit the development of cardiac hypertrophy and fibrosis, thereby improving LV function. Both in vitro experiments and mouse models confirmed the effects of Zer on cardiac cells and cardiac fibroblasts.
Article
Cardiac & Cardiovascular Systems
Elisangela C. P. Lopes, Layde R. Paim, Luis F. R. S. Carvalho-Romano, Edmilson R. Marques, Eduarda O. Z. Minin, Camila F. L. Vegian, Jose A. Pio-Magalhaes, Licio A. Velloso, Otavio R. Coelho-Filho, Andrei C. Sposito, Jose R. Matos-Souza, Wilson Nadruz, Roberto Schreiber
Summary: This study evaluated the relationship between circulating miRNAs and left ventricular hypertrophy (LVH) in hypertensive patients. The results showed that miR-145-5p, miR-451, and let7c were independently associated with LVH and left ventricular mass index. These miRNAs were also found to regulate genes and pathways related to cardiac remodeling.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2022)
Article
Biochemistry & Molecular Biology
Aleksandra Paterek, Marta Okninska, Michal Maczewski, Urszula Mackiewicz
Summary: This study found that right ventricular failure caused by left ventricular failure cannot be solely explained by a decline in cardiomyocyte function. Other factors may play a role, highlighting the need for further research to better understand the biology of right ventricular failure and develop targeted therapies.
Article
Medicine, Research & Experimental
Jingfu Bao, Yinghui Lu, Qinying She, Weijuan Dou, Rong Tang, Xiaodong Xu, Mingchao Zhang, Ling Zhu, Qing Zhou, Hui Li, Guohua Zhou, Zhongzhou Yang, Shaolin Shi, Zhihong Liu, Chunxia Zheng
Summary: In CKD rats, restoration of cardiomyocyte-specific miRNA-30 helps to alleviate LVH, while blockade of miRNA-30 leads to cardiomyocyte hypertrophy. CKD-related factors suppress cardiac miRNA-30 expression, while supplementation of miRNA-30 mitigates cardiomyocyte hypertrophy induced by these factors.
Review
Cardiac & Cardiovascular Systems
Alia S. Alhakak, John R. Teerlink, Joann Lindenfeld, Michael Boehm, Giuseppe M. C. Rosano, Tor Biering-Sorensen
Summary: LVET is the time interval from aortic valve opening to closure in which the left ventricle ejects blood into the aorta. It has long been used to assess left ventricular function and contractility, but recent interest focuses on its use as a measure of therapeutic action for heart failure patients. This review provides an overview of LVET measurement methods, mechanistic understanding, association with outcomes, mechanisms behind LVET shortening in heart failure, and potential drug implications.
EUROPEAN JOURNAL OF HEART FAILURE
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Charlene A. Mauger, Kathleen Gilbert, Avan Suinesiaputra, David A. Bluemke, Colin O. Wu, Joao A. C. Lima, Alistair A. Young, Bharath Ambale-Venkatesh
Summary: This study aimed to quantify the relationship between left ventricular (LV) three-dimensional shape at MRI and incident cardiovascular events over 10 years. Results showed that adding LV remodeling signatures to traditional cardiovascular risk factors improved the prediction of heart failure, coronary heart disease, and cardiovascular disease events over 10 years.
Article
Peripheral Vascular Disease
Alexander C. Egbe, William R. Miranda, Carole A. Warnes, Crystal Bonnichsen, Juan Crestanello, Jason H. Anderson, Heidi M. Connolly
Summary: The study aimed to analyze procedural outcomes, hemodynamic improvement, regression of left ventricular mass hypertrophy, and cardiovascular events following repair of coarctation of aorta (COA). Results indicated that persistent hypertension post-repair was associated with suboptimal left ventricular mass index regression and cardiovascular events, suggesting that optimal blood pressure control with medical therapy may lead to improved outcomes.
Article
Cardiac & Cardiovascular Systems
Michinari Hieda, Satyam Sarma, Christopher M. Hearon, James P. MacNamara, Katrin A. Dias, Mitchel Samels, Dean Palmer, Sheryl Livingston, Margot Morris, Benjamin D. Levine
Summary: The study suggests that high-intensity exercise training can reduce LV myocardial stiffness in patients with LV hypertrophy, thus helping to prevent the development of heart failure.
Review
Cardiac & Cardiovascular Systems
Brian P. Halliday, Roxy Senior, Dudley J. Pennell
Summary: The measurement of left ventricular ejection fraction (LVEF) has been a key component in imaging studies for cardiac patients, but its utility as a prognostic indicator has diminished in certain populations such as heart failure patients with preserved ejection fraction (HF-PEF) and those with valvular heart disease. Assessing myocardial strain, particularly global longitudinal strain (GLS), holds promise in improving risk stratification and therapy selection for these patients. Additional studies are needed to fully integrate GLS into routine clinical practice and improve patient outcomes.
EUROPEAN HEART JOURNAL
(2021)
Article
Cardiac & Cardiovascular Systems
Katharina Mederle, Bernhard Gess, Florentina Pluteanu, Jelena Plackic, Klaus-Juergen Tiefenbach, Alexandra Grill, Jens Kockskaemper, Hayo Castrop
CARDIOVASCULAR RESEARCH
(2016)
Article
Cardiac & Cardiovascular Systems
Beatrix Scholz, Jan Sebastian Schulte, Sabine Hamer, Kirsten Himmler, Florentina Pluteanu, Matthias Dodo Seidl, Juliane Stein, Eva Wardelmann, Elke Hammer, Uwe Voelker, Frank Ulrich Mueller
CIRCULATION-ARRHYTHMIA AND ELECTROPHYSIOLOGY
(2019)
Article
Biochemistry & Molecular Biology
Alexander Heinick, Florentina Pluteanu, Christina Hermes, Andre Klemme, Manuel Domnik, Xenia Husser, Volker Gerke, Wilhelm Schmitz, Frank U. Mueller
Article
Biochemistry & Molecular Biology
Matthias D. Seidl, Benedikt Fels, Daniel Kranick, Alexandra Sternberg, Kristina Grimm, Frank T. Stuempel, Florentina Pluteanu, Jan S. Schulte, Alexander Heinick, Nobuhiko Kojima, Shogo Endo, Andreas Huge, Monika Stoll, Frank U. Mueller
Article
Cardiac & Cardiovascular Systems
Florentina Pluteanu, Matthias D. Seidl, Sabine Hamer, Beatrix Scholz, Frank U. Mueller
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2020)
Article
Cardiac & Cardiovascular Systems
Florentina Pluteanu, Peter Boknik, Alexander Heinick, Christiane Koenig, Frank U. Mueller, Adam Weidlich, Uwe Kirchhefer
Summary: The phosphorylation of B56 alpha at Ser(41) by PKC is involved in the regulation of myocyte Ca2+ cycling and contraction. PKC activation leads to a decrease in PP2A activity and an increase in myocyte contraction and intracellular Ca2+ signaling. PKC-mediated inhibition of PP2A also modulates the activation and inactivation kinetics of LTCC.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY
(2022)
Letter
Cardiac & Cardiovascular Systems
Florentina Pluteanu, Uwe Kirchhefer
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY
(2022)
Review
Cell Biology
Jens Kockskaemper, Florentina Pluteanu
Summary: Arterial hypertension affects approximately 1 billion people worldwide, resulting in increased morbidity and mortality. In addition to cardiac damage such as left ventricular hypertrophy, dysfunction, and heart failure, hypertension also causes left atrial remodeling, potentially leading to atrial contractile dysfunction and atrial fibrillation. This review examines the various aspects of left atrial remodeling in hypertension, identifying potential mechanisms and discussing its consequences for atrial and ventricular function.
Meeting Abstract
Pharmacology & Pharmacy
F. Pluteanu, M. Domnik, C. Rolfes, A. Klemme, A. Heinick, F. U. Mueller
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
(2019)
Meeting Abstract
Pharmacology & Pharmacy
M. Domnik, F. Pluteanu, C. Rolfes, A. Klemme, A. Heinick, F. U. Mueller
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
(2019)
Meeting Abstract
Cardiac & Cardiovascular Systems
D. Glaser, F. Pluteanu, A. Heinick, F. U. Mueller, P. Boknik, U. Kirchhefer
EUROPEAN HEART JOURNAL
(2018)
Article
Cardiac & Cardiovascular Systems
Matthias D. Seidl, Juliane Stein, Sabine Hamer, Florentina Pluteanu, Beatrix Scholz, Eva Wardelmann, Andreas Huge, Anika Witten, Monika Stoll, Elke Hammer, Uwe Voelker, Frank U. Mueller
CIRCULATION-ARRHYTHMIA AND ELECTROPHYSIOLOGY
(2017)
Meeting Abstract
Pharmacology & Pharmacy
M. D. Seidl, J. Stein, S. Hamer, F. Pluteanu, B. Scholz, E. Wardelmann, A. Huge, A. Witten, M. Stoll, E. Hammer, U. Voelker, F. U. Mueller
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
(2017)
Meeting Abstract
Pharmacology & Pharmacy
F. Pluteanu, M. Seidl, B. Scholz, S. Hamer, F. U. Mueller
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
(2017)
Article
Cardiac & Cardiovascular Systems
Andrew B. Harvey, Renelyn A. Woltes, Raymond N. Deepe, Hannah G. Tarolli, Jenna R. Drummond, Allison Trouten, Auva Zandi, Jeremy L. Barth, Rupak Mukherjee, Martin J. Romeo, Silvia G. Vaena, Ge Tao, Robin Muise-Helmericks, Paula S. Ramos, Russell A. Norris, Andy Wessels
Summary: This study highlights the importance of SOX9 in the regulation of epicardial cell invasion and emphasizes the role of EPDCs in regulating atrioventricular valve development and homeostasis. It also reports a novel expression profile of Cd109, a gene with previously unknown relevance in heart development.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
(2024)
Review
Cardiac & Cardiovascular Systems
MariaSanta C. Mangione, Jinhua Wen, Dian J. Cao
Summary: mTOR, a mechanistic target of rapamycin, is an evolutionarily conserved pathway that plays a fundamental role in nutrient sensing, growth, metabolism, lifespan, and aging. Recent studies have highlighted the regulatory role of mTOR in innate immune responses and its involvement in the pathogenesis of cardiovascular diseases, especially in acute inflammation and atherosclerotic cardiovascular disease. This review also discusses mTOR's role in trained immunity, immune senescence, and clonal hematopoiesis, as well as its architecture and regulatory complexes.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
(2024)
Article
Cardiac & Cardiovascular Systems
Junlin Li, Yajun Gong, Yiren Wang, Huihui Huang, Huan Du, Lianying Cheng, Cui Ma, Yongxiang Cai, Hukui Han, Jianhong Tao, Gang Li, Panke Cheng
Summary: Myocardial ischemia-reperfusion injury is closely related to the final infarct size in acute myocardial infarction. Regulatory T cells play an important role in the inflammatory response after AMI, but different subtypes of Tregs have different effects on the injury.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
(2024)
Article
Cardiac & Cardiovascular Systems
Yuxin Chu, Yutao Hua, Lihao He, Jin He, Yunxi Chen, Jing Yang, Ismail Mahmoud, Fanfang Zeng, Xiaochang Zeng, Gloria A. Benavides, Victor M. Darley-Usmar, Martin E. Young, Scott W. Ballinger, Sumanth D. Prabhu, Cheng Zhang, Min Xie
Summary: This study demonstrates that administering beta-hydroxybutyrate (beta-OHB) at the time of reperfusion can reduce infarct size and preserve cardiac function by activating autophagy and preserving mitochondrial homeostasis, potentially through mTOR inhibition.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
(2024)